A systematic review of RdRp of SARS-CoV-2 through artificial intelligence and machine learning utilizing structure-based drug design strategy

Since the coronavirus disease has been declared a global pandemic, it had posed a challenge among researchers and raised common awareness and collaborative efforts towards finding the solution. Caused by severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2), coronavirus drug design strategy needs to be optimized. It is understandable that cognizance of the pathobiology of COVID-19 can help scientists in the development and discovery of therapeutically effective antiviral drugs by elucidating the unknown viral pathways and structures. Considering the role of artificial intelligence and machine learning with its advancements in the field of science, it is rational to use these methods which can aid in the discovery of new potent candidates in silico. Our review utilizes similar methodologies and focuses on RNA-dependent RNA polymerase (RdRp), based on its importance as an essential element for virus replication and also a promising target for COVID-19 therapeutics. Artificial neural network technique was used to shortlist articles with the support of PRISMA, from different research platforms including Scopus, PubMed, PubChem, and Web of Science, through a combination of keywords. “English language”, from the year “2000” and “published articles in journals” were selected to carry out this research. We summarized that structural details of the RdRp reviewed in this analysis will have the potential to be taken into consideration when developing therapeutic solutions and if further multidisciplinary efforts are taken in this domain then potential clinical candidates for RdRp of SARS-CoV-2 could be successfully delivered for experimental validations.

PDF

___

1. Bullock J, Luccioni A, Pham KH, Lam CSN, Luengo-Oroz M. Mapping the landscape of artificial intelligence applications against COVID-19. Journal of Artificial Intelligence Research 2020; 69: 807-45.
2. Villas-Boas GR, Rescia VC, Paes MM, Lavorato SN, Magalhães-Filho MFd et al. The new coronavirus (SARS-CoV-2): a comprehensive review on immunity and the application of bioinformatics and molecular modeling to the discovery of potential anti-SARS-CoV-2 agents. Molecules 2020; 25: 4086.
3. Lavecchia A. Deep learning in drug discovery: opportunities, challenges and future prospects. Drug Discovery Today 2019; 24: 2017-32.
4. Zhong F, Xing J, Li X, Liu X, Fu Z et al. Artificial intelligence in drug design. Science China Life Sciences 2018; 61: 1191- 204.
5. Bengio Y, LeCun Y. Scaling learning algorithms towards AI. Large-Scale Kernel Machines 2007; 34: 1-41.
6. Yanqing D, Edwards J, Dwivedi Y. Artificial intelligence for decision making in the era of Big Data. International Journal of Information Management 2019; 48: 63-71.
7. Ahidjo BA, Loe MWC, Ng YL, Mok CK, Chu JJH. Current perspective of antiviral strategies against COVID-19. ACS Infectious Diseases 2020; 6: 1624-34.
8. Brownlee C. In Nano, Volume 14, Issue 5. ACS Publications; 2020.
9. Fan Z, Yao B, Ding Y, Zhao J, Xie M et al. Entropy-driven amplified electrochemiluminescence biosensor for RdRp gene of SARS-CoV-2 detection with self-assembled DNA tetrahedron scaffolds. Biosensors and Bioelectronics 2021; 178: 113015.
10. Tian L, Qiang T, Liang C, Ren X, Jia M et al. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. European Journal of Medicinal Chemistry 2021: 113201.
11. Khan RJ, Jha R, Amera GM, Jain M, Singh E et al. Targeting Novel Coronavirus 2019: A systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2’-O-Ribose methyltransferase. Journal of Biomolecular Structure & Dynamics 2020: 1-14.
12. Hilgenfeld R, Peiris M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral research 2013; 100: 286-95.
13. Li L, Qin L, Xu Z, Yin Y, Wang X et al. Artificial intelligence distinguishes COVID-19 from community acquired pneumonia on chest CT. Radiology 2020.
14. Arao DA. Pandemic discourse. Taylor & Francis; 2021.
15. Ghaebi M, Osali A, Valizadeh H, Roshangar L, Ahmadi M. Vaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances. Journal of Cellular Physiology 2020; 235: 9098-109.
16. Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R et al. COVID-19 vaccine trials should seek worthwhile efficacy. The Lancet 2020; 396: 741-3.
17. Shen W, Yang C, Gao L. Address business crisis caused by COVID-19 with collaborative intelligent manufacturing technologies. IET Collaborative Intelligent Manufacturing 2020; 2: 96-9.
18. Wang Q, Wu J, Wang H, Gao Y, Liu Q et al. Structural basis for RNA replication by the SARS-CoV-2 polymerase. Cell 2020; 182: 417-28. e13.
19. Yao X, Ye F, Zhang M, Cui C, Huang B et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 2020; 71: 732-9.
20. Fehr A, HJ PSM, Bickerton E, Britton P. An Overview of Their Replication and Pathogenesis; Section 2 Genomic Organization. Methods in Molecular Biology Springer 2015; 1282: 1-23.
21. Zhou Y, Hou Y, Shen J, Huang Y, Martin W et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery 2020; 6: 1-18.
22. Posthuma CC, Te Velthuis AJ, Snijder EJ. Nidovirus RNA polymerases: complex enzymes handling exceptional RNA genomes. Virus Research 2017; 234: 58-73.
23. Snijder E, Decroly E, Ziebuhr J. The nonstructural proteins directing coronavirus RNA synthesis and processing. Advances in Virus Research 2016; 96: 59-126.
24. Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D et al. Structure of replicating SARS-CoV-2 polymerase. Nature 2020; 584: 154-6.
25. Ahn D-G, Choi J-K, Taylor DR, Oh J-W. Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates. Archives of Virology 2012; 157: 2095-104.
26. Subissi L, Posthuma CC, Collet A, Zevenhoven-Dobbe JC, Gorbalenya AE et al. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proceedings of the National Academy of Sciences 2014; 111: E3900-E9.
27. Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nature Communications 2019; 10: 1-9.
28. Gao Y, Yan L, Huang Y, Liu F, Zhao Y et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 2020; 368: 779-82.
29. Gerçek Z, Ceyhan D, Erçağ E. Synthesis and molecular docking study of novel COVID-19 inhibitors. Turkish Journal of Chemistry 2021; 45: 704.
30. Slanina H, Madhugiri R, Bylapudi G, Schultheiß K, Karl N et al. Coronavirus replication–transcription complex: Vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit. Proceedings of the National Academy of Sciences 2021; 118.
31. Gerlach P, Malet H, Cusack S, Reguera J. Structural insights into bunyavirus replication and its regulation by the vRNA promoter. Cell 2015; 161: 1267-79.
32. Kinsella E, Martin SG, Grolla A, Czub M, Feldmann H, Flick R. Sequence determination of the Crimean–Congo hemorrhagic fever virus L segment. Virology 2004; 321: 23-8.
33. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Structural Biology 1999; 6: 937-43.
34. Xu X, Liu Y, Weiss S, Arnold E, Sarafianos SG et al. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Research 2003; 31: 7117-30.
35. Jia H, Gong P. A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses. Frontiers in Microbiology 2019; 10: 1945.
36. Robson B. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Computers in Biology and Medicine 2020; 119: 103670.
37. Candido DDS, Watts A, Abade L, Kraemer MU, Pybus OG et al. Routes for COVID-19 importation in Brazil. Journal of Travel Medicine 2020; 27: taaa042.
38. Zhang L, Lin D, Sun X, Curth U, Drosten C et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020; 368: 409-12.
39. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367: 1260-3.
40. Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3′ and 5′ ends. Virus Research 2015; 206: 120-33.
41. Park S-J, Kim Y-G, Park H-J. Identification of RNA pseudoknot-binding ligand that inhibits the− 1 ribosomal frameshifting of SARScoronavirus by structure-based virtual screening. Journal of the American Chemical Society 2011; 133: 10094-100.
42. Alipanahi B, Delong A, Weirauch MT, Frey BJ. Predicting the sequence specificities of DNA-and RNA-binding proteins by deep learning. Nature Biotechnology 2015; 33: 831-8.
43. Jaafar ZA, Kieft JS. Viral RNA structure-based strategies to manipulate translation. Nature Reviews Microbiology 2019; 17: 110-23.
44. Plant EP, Dinman JD. The role of programmed-1 ribosomal frameshifting in coronavirus propagation. Frontiers in Bioscience: A Journal and Virtual Library 2008; 13: 4873.
45. Stammler SN, Cao S, Chen S-J, Giedroc DP. A conserved RNA pseudoknot in a putative molecular switch domain of the 3′-untranslated region of coronaviruses is only marginally stable. Rna 2011; 17: 1747-59.
46. Rangan R, Zheludev IN, Das R. RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses. BioRxiv 2020.
47. Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. EXCLI Journal 2020; 19: 410.
48. Gorbalenya AE, Baker SC, Baric R, Groot RJd, Drosten C et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Study Group. Nature Microbiology 2020. doi: 10.1038/s41564-020-0695-z
49. Kandeil A, Shehata MM, El Shesheny R, Gomaa MR, Ali MA et al. Complete genome sequence of Middle East respiratory syndrome coronavirus isolated from a dromedary camel in Egypt. Genome Announcements 2016; 4.
50. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A et al. The genome sequence of the SARS-associated coronavirus. Science 2003; 300: 1399-404.
51. Pérez-Losada M, Arenas M, Galán JC, Bracho MA, Hillung J et al. High-throughput sequencing (HTS) for the analysis of viral populations. Infection, Genetics and Evolution 2020; 80: 104208.
52. Richter J, Tryfonos C, Tourvas A, Floridou D, Paphitou NI et al. Complete Genome sequence of West Nile virus (WNV) from the first human case of neuroinvasive WNV infection in Cyprus. Genome Announcements 2017; 5.
53. Lehmann KC, Gulyaeva A, Zevenhoven-Dobbe JC, Janssen GM, Ruben M et al. Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. Nucleic Acids Research 2015; 43: 8416-34.
54. Picarazzi F, Vicenti I, Saladini F, Zazzi M, Mori M. Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. Molecules 2020; 25: 5695.
55. Lu G, Gong P. Crystal structure of the full-length Japanese encephalitis virus NS5 reveals a conserved methyltransferase-polymerase interface. PLoS Pathogens 2013; 9: e1003549.
56. Yu W, Hui D, Chan-Yeung M. Antiviral agents and corticosteroids in the treatment of severe acute respiratory syndrome (SARS). BMJ Publishing Group Ltd; 2004.
57. Athanasios T, Psychos C, Domenikos S. Communication: Novel drug combination Doxycycline-Melatonin-Digoxin (DMD) for possible Covid-19 treatment. Journal of Modern Medicinal Chemistry 2020; 8: 1-3.
58. Kalhor H, Sadeghi S, Abolhasani H, Kalhor R, Rahimi H. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches. Journal of Biomolecular Structure and Dynamics 2020: 1-16.
59. de Oliveira OV, Rocha GB, Paluch AS, Costa LT. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening. Journal of Biomolecular Structure and Dynamics 2021; 39: 3924-33.
60. Pollard BS, Blanco JC, Pollard JR. Classical drug digitoxin inhibits influenza cytokine storm, with implications for COVID-19 therapy. in vivo 2020; 34: 3723-30.
61. Sekhar T. Virtual Screening based prediction of potential drugs for COVID-19. Combinatorial Chemistry & High Throughput Screening 2020; 23.
62. Wu C, Liu Y, Yang Y, Zhang P, Zhong W et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B 2020; 10: 766-88.
63. Manickavasagam P. Spike protein of SARS-CoV-2: impact of single amino acid mutation and effect of drug binding to the variant-in silico analysis. 2020.
64. Wu Y, Li Z, Zhao YS, Huang YY, Jiang MY et al. Therapeutic targets and potential agents for the treatment of COVID‐19. Medicinal Research Reviews 2021; 41: 1775-97.
65. Baby K, Maity S, Mehta CH, Suresh A, Nayak UY et al. Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19. F1000Research 2020; 9.
66. Smith M, Smith JC. Repurposing therapeutics for COVID-19: Supercomputer-based docking to the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface. 2020.
67. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences 2020; 248: 117477.
68. Elfiky AA. Zika viral polymerase inhibition using anti‐HCV drugs both in market and under clinical trials. Journal of Medical Virology 2016; 88: 2044-51.
69. Elfiky AA, Ismail A. Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV. Life Sciences 2019; 238: 116958.
70. Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure‐activity relationship and molecular docking revealed a potency of anti‐ hepatitis C virus drugs against human corona viruses. Journal of Medical Virology 2017; 89: 1040-7.
71. Ezat AA, Elfiky AA, Elshemey WM, Saleh NA. Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study. VirusDisease 2019; 30: 207-13.
72. Markland W, McQuaid T, Jain J, Kwong A. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrobial Agents and Chemotherapy 2000; 44: 859-66.
73. McQuaid T, Savini C, Seyedkazemi S. Sofosbuvir, a significant paradigm change in HCV treatment. Journal of Clinical and Translational Hepatology 2015; 3: 27.
74. Wang M, Cao R, Zhang L, Yang X, Liu J et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro. Cell Research 2020; 30: 269-71.
75. Yang PL, Gao M, Lin K, Liu Q, Villareal VA. Anti-HCV drugs in the pipeline. Current Opinion in Virology 2011; 1: 607-16.
76. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J et al. First case of 2019 novel coronavirus in the United States. New England Journal of Medicine 2020.
77. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine 2017; 9.
78. Yin W, Mao C, Luan X, Shen D-D, Shen Q et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020; 368: 1499-504.
79. Ahmad J, Ikram S, Ahmad F, Rehman IU, Mushtaq M. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp)–A drug repurposing study. Heliyon 2020; 6: e04502.
80. Ahmad M, Dwivedy A, Mariadasse R, Tiwari S, Kar D et al. Prediction of Small Molecule Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus-2 RNA-dependent RNA Polymerase. ACS Omega 2020; 5: 18356-66.
81. Choi KH, Groarke JM, Young DC, Kuhn RJ, Smith JL et al. The structure of the RNA-dependent RNA polymerase from bovine viral diarrhea virus establishes the role of GTP in de novo initiation. Proceedings of the National Academy of Sciences 2004; 101: 4425-30.
82. Abd-Elsalam KA. Bioinformatic tools and guideline for PCR primer design. African Journal of Biotechnology 2003; 2: 91-5.
83. Kim Y, Jedrzejczak R, Maltseva NI, Wilamowski M, Endres M et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS‐ CoV‐2. Protein Science 2020; 29: 1596-605.